PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Worst Case Consideration, page-17

  1. 9,704 Posts.
    lightbulb Created with Sketch. 1234
    No issue and in fact this is one of the keys to our investment moat via exclusive contract with Bene who is only FDA approved manufacturer of PPS.

    You may like to avail yourself with the excellent company presentations and brokerage reports. Within which is great detail including such matters being raised around safety, efficacy and Bene's history.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.